,address1,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Medicon Village,Lund,223 81,Sweden,46 4 62 75 65 00,https://www.xintela.se,Biotechnology,Healthcare,"Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company develops products based on XINMARK, a patented technology platform; XSTEM, a stem cell platform for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; EQSTEM for the joint disease treatment in horses; CANISTEM for stem cell treatment in dogs; and XACT, an analytical test for cartilage cells. It is also involved in the development of TARG9 and TARG10, therapeutic antibodies targeting integrin aiopi for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. The company's trademarks also include XINTELA and TARGINTA. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",25,"{'maxAge': 1, 'name': 'Mr. Gregory  Batcheller B.Sc., J.D., L.L.M., LLM', 'age': 65, 'title': 'Exec. Chairman', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 383000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.25,0.26,0.244,0.26,0.25,0.26,0.244,0.26,0.0,1.556681,163607,163607,304618,239610,239610,0.246,0.26,0,0,82429712,0.2,0.58,0.26216,0.3396025,0.0,0.0,SEK,76811464,0.0,149376031,307572992,0.07891,0.17452,-0.093,1672444800,1703980800,1688083200,-65135000,-0.08,-1.197,STO,EQUITY,XINT.ST,XINT.ST,Xintela AB,Xintela AB (publ),1458633600,Europe/Stockholm,CEST,7200000,0.252,none,697000,0.002,-64179000,0,0.222,0.25,-3.32135,-49017624,-69134000,0.0,0.0,0.0,SEK,
1,Medicon Village,Lund,223 81,Sweden,46 4 62 75 65 00,https://www.xintela.se,Biotechnology,Healthcare,"Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company develops products based on XINMARK, a patented technology platform; XSTEM, a stem cell platform for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; EQSTEM for the joint disease treatment in horses; CANISTEM for stem cell treatment in dogs; and XACT, an analytical test for cartilage cells. It is also involved in the development of TARG9 and TARG10, therapeutic antibodies targeting integrin aiopi for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. The company's trademarks also include XINTELA and TARGINTA. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",25,"{'maxAge': 1, 'name': 'Dr. Evy  Lundgren-Ã…kerlund Assoc.Prof, BSc, Ph.D.', 'age': 65, 'title': 'Chief Exec. Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 3655000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.25,0.26,0.244,0.26,0.25,0.26,0.244,0.26,0.0,1.556681,163607,163607,304618,239610,239610,0.246,0.26,0,0,82429712,0.2,0.58,0.26216,0.3396025,0.0,0.0,SEK,76811464,0.0,149376031,307572992,0.07891,0.17452,-0.093,1672444800,1703980800,1688083200,-65135000,-0.08,-1.197,STO,EQUITY,XINT.ST,XINT.ST,Xintela AB,Xintela AB (publ),1458633600,Europe/Stockholm,CEST,7200000,0.252,none,697000,0.002,-64179000,0,0.222,0.25,-3.32135,-49017624,-69134000,0.0,0.0,0.0,SEK,
2,Medicon Village,Lund,223 81,Sweden,46 4 62 75 65 00,https://www.xintela.se,Biotechnology,Healthcare,"Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company develops products based on XINMARK, a patented technology platform; XSTEM, a stem cell platform for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; EQSTEM for the joint disease treatment in horses; CANISTEM for stem cell treatment in dogs; and XACT, an analytical test for cartilage cells. It is also involved in the development of TARG9 and TARG10, therapeutic antibodies targeting integrin aiopi for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. The company's trademarks also include XINTELA and TARGINTA. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",25,"{'maxAge': 1, 'name': 'Mr. Gunnar  Telhammar', 'age': 61, 'title': 'CFO & Fin. Director', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.25,0.26,0.244,0.26,0.25,0.26,0.244,0.26,0.0,1.556681,163607,163607,304618,239610,239610,0.246,0.26,0,0,82429712,0.2,0.58,0.26216,0.3396025,0.0,0.0,SEK,76811464,0.0,149376031,307572992,0.07891,0.17452,-0.093,1672444800,1703980800,1688083200,-65135000,-0.08,-1.197,STO,EQUITY,XINT.ST,XINT.ST,Xintela AB,Xintela AB (publ),1458633600,Europe/Stockholm,CEST,7200000,0.252,none,697000,0.002,-64179000,0,0.222,0.25,-3.32135,-49017624,-69134000,0.0,0.0,0.0,SEK,
3,Medicon Village,Lund,223 81,Sweden,46 4 62 75 65 00,https://www.xintela.se,Biotechnology,Healthcare,"Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company develops products based on XINMARK, a patented technology platform; XSTEM, a stem cell platform for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; EQSTEM for the joint disease treatment in horses; CANISTEM for stem cell treatment in dogs; and XACT, an analytical test for cartilage cells. It is also involved in the development of TARG9 and TARG10, therapeutic antibodies targeting integrin aiopi for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. The company's trademarks also include XINTELA and TARGINTA. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",25,"{'maxAge': 1, 'name': 'Dr. Per Goran Oskar Norlen', 'age': 52, 'title': 'Chief Medical Officer', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.25,0.26,0.244,0.26,0.25,0.26,0.244,0.26,0.0,1.556681,163607,163607,304618,239610,239610,0.246,0.26,0,0,82429712,0.2,0.58,0.26216,0.3396025,0.0,0.0,SEK,76811464,0.0,149376031,307572992,0.07891,0.17452,-0.093,1672444800,1703980800,1688083200,-65135000,-0.08,-1.197,STO,EQUITY,XINT.ST,XINT.ST,Xintela AB,Xintela AB (publ),1458633600,Europe/Stockholm,CEST,7200000,0.252,none,697000,0.002,-64179000,0,0.222,0.25,-3.32135,-49017624,-69134000,0.0,0.0,0.0,SEK,
